Anti-tumor necrosis factor-α-induced psoriasis

Journal of Rheumatology

Volumn 33, Issue 7, 2006, Pages 1411-1414

  Sari, Ismail ^a   Akar, Servet ^a   Birlik, Merih ^a   Sis, Banu ^b   Onen, Fatos ^a   Akkoc, Nurullah ^a,c  

^a Division of Rheumatology   (Turkey)

^b Department of Pathology ^*

^c DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Adverse effect; Psoriasis; Tumor necrosis factor inhibitors

Indexed keywords

CORTICOSTEROID; DICLOFENAC; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ANTI TUMOR NECROSIS FACTOR ALPHA INDUCED PSORIASIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE EXACERBATION; DRUG INDUCED DISEASE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; PRIORITY JOURNAL; PSORIASIS; RASH; RECURRENT DISEASE; RHEUMATOID ARTHRITIS; SKIN BIOPSY; SYMPTOM;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DICLOFENAC; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; METHOTREXATE; PREDNISONE; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33745780728     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Furst DE, Keystone EC, Breedveld FC, et al. Updated consensus Statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001). Ann Rheum Dis 2001;60 Suppl 3:iii2-5.
2. Sobell JM. Overview of biologic agents in medicine and dermatology. Semin Cutan Med Surg 2005;24:2-9.
3. Hyrich KL, Silman AJ, Watson KD, Symmons DP. Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis 2004;63:1538-43.
4. Kary S, Worm M, Audring H, et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor (alpha) antagonists. Ann Rheum Dis 2006;65:405-7.
5. Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: A paradoxical adverse reaction. Arthritis Rheum 2005;52:2513-8.
6. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
7. Helliwell PS, Taylor WJ. Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis 2005;64 Suppl 2:ii3-8.
8. Tsankov N, Kazandjieva J, Drenovska K. Drugs in exacerbation and provocation of psoriasis. Clin Dermatol 1998;16:333-51.
9. Cohen AD, Bonneh DY, Reuveni H, Vardy DA, Naggan L, Halevy S. Drug exposure and psoriasis vulgaris: case-control and case-crossover studies. Acta Derm Venereol 2005;85:299-303.
10. Beuthien W, Mellinghoff HU, von Kempis J. Skin reaction to adalimumab. Arthritis Rheum 2004;50:1690-2.
11. Verea MM, Del Pozo J, Yebra-Pimentel MT. Porta A, Fonseca E. Psoriasiform eruption induced by infliximab. Ann Pharmacother 2004;38:54-7.
12. Thurber M, Feasel A, Stroehlein J, Hymes SR. Pustular psoriasis induced by infliximab. J Drugs Dermatol 2004;3:439-40.
13. Haibel H, Spiller I, Strasser C, Rudwaleit M, Dorner T, Sieper J. Unexpected new onset or exacerbation of psoriasis in treatment of active ankylosing spondylitis with TNF-alpha blocking agents: four case reports. Ann Rheum Dis 2004;63 Suppl:405.
14. Grinblat B, Scheinberg M. Unexpected onset of psoriasis during infliximab treatment: comment on the article by Beuthien et al [letter]. Arthritis Rheum 2005;52:1333-4; author reply 1334.
15. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139:1627-32; discussion 1632.
16. Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005;7:R666-76.
17. Dereure O, Guillot B, Jorgensen C, Cohen J-D, Combes B, Guilhou J-J. Psoriatic lesions induced by antitumour necrosis factor-treatment: two cases. Br J Dermatol 2004;151:506-7.
18. Baeten D, Kruithof E, van den Bosch F, et al. Systematic safety followup in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 2003;62:829-34.
19. Tobin AM, Kirby B. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs 2005;19:47-57.
20. Calabrese LH. Molecular differences in anticytokine therapies. Clin Exp Rheumatol 2003;21:241-8.
21. Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J. Upregulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. Ann Rheum Dis 2003;62:561-4.
22. Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J. Downregulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum 2003;48:780-90.
23. Lowes MA, Lew W, Krueger JG. Current concepts in the immunopathogenesis of psoriasis. Dermatol Clin 2004;22:349-69, vii.